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Objectives. This study sought o determine the long-term out- 
come of adult patients undergoing percutaneous balloon aortic 
valvuloplasty. 
Background. Percutaneous balloon aortic valvuloplasty has 
been offered as an alternative to aortic valve replacement for 
selected patients with valvular aortic stenosis. Although balloon 
aortic valvuloplasty produces an immediate reduction in the 
transvalvular aortic gradient, a high incidence of restenosis 
frequently leads to recurrent symptoms. Therefore, it is unclear 
whether balloon aortic valvuloplasty impacts on the long-term 
outcome of these patients. 
Methods. Clinical, hemodynamic and echocardiographic data 
were collected at baseline in 165 patients undergoing balloon 
aortic valvuloplasty and examined for their ability to predict 
long-term outcome. 
Results. The median duration of follow-up was 3.9 years (range 
1 to 6). Ninety-nine percent follow-up was achieved. During this 
6-year period, 152 patients (93%) died or underwent aortic valve 
replacement, and 99 (60%) died of cardiac-related causes. The 
probability of event-free survival (freedom from death, aortic 
valve replacement orrepeat balloon aortic valvuloplasty) 1,2 and 
3 years after valvuloplasty was 40%, 19% and 6%, respectively. In 
contrast, the probability of survival 3 years after balloon aortic 
valvuloplasty in a subset of 42 patients who underwent subsequent 
aortic valve replacement was 84%. Survival after aortic valvulo- 
plasty was poor regardless of the presenting symptom, but pa- 
tients with New York Heart Association functional class IV 
congestive heart failure had events earliest. Univariable predic- 
tors of decreased event-free survival were younger age, advanced 
congestive heart failure symptoms, lower ejection fraction, ele- 
vated left ventricular end-diastolic pressure, presence of coronary 
artery disease and increased left ventricular internal diastolic 
diameter. Stepwise multivariable logistic regression analysis 
found that only younger age and a lower left ventricular ejection 
fraction contributed independent adverse prognostic information 
(chi-sqnare 14.89, p = 0.0006). 
Conclusions. Long-term event.free and actuarial survival after 
balloon aortic valvuloplasty is dismal and resembles the natural 
history of untreated aortic stenosis. Aortic valve replacement may 
be performed in selected subjects with good results. However, the 
prognosis for the remainder ofpatients who are not candidates for 
aortic valve replacement is particularly poor. 
(J Am CoU Cardiol 1995;26:1522-8) 
Percutaneous balloon aortic valvuioplasty has been used as an 
alternative to surgical valve replacement for patients with 
calcific aortic stenosis ince 1986 (1). Acutely, balloon aortic 
valvuloplasty usually reduces the aortic valvular gradient, 
increases the calculated aortic valve area and improves left 
ventricular ejection fraction (2-4); yet, short- and intermediate- 
term follow-up data indicate that cardiac hemodynamic vari- 
ables may revert o their prevalvuloplasty baseline as early as 
2 h after the procedure (5). Within 6 months, 75% of patients 
who have undergone an aortic valvuloplasty exhibit hemody- 
namic evidence of restenosis (6-8). Therefore, it is unclear 
whether balloon aortic valvuloplasty favorably alters the long- 
term outcome of patients with symptomatic aortic stenosis. 
The present study describes the long-term outcome (medi- 
an follow-up 3.9 years, range 1 to 6) of 165 patients undergoing 
balloon aortic valvuloplasty for severe aortic stenosis. It also 
defines the clinical, invasive and echocardiographic variables 
related to long-term outcome after this procedure. 
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Methods  
Patients. Between November 11, 1986 and April 30, 1991, 
165 patients with symptomatic valvular aortic stenosis under- 
went balloon aortic valvuloplasty at Duke University Medical 
Center. All patients had been previously evaluated by both a 
cardiologist and a cardiothoracic surgeon. Balloon aortic val- 
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vuloplasty was most often performed because the operative 
mortality rate associated with valve replacement was estimated 
to exceed 15%. Exceptions include 17 operative candidates 
who requested balloon valvuloplasty as an alternative to sur- 
gical valve replacement and 4 who underwent palliative bal- 
loon aortic valvuloplasty during severe noncardiac illnesses. 
Forty-two of the original 165 study patients underwent 
aortic valve replacement after undergoing balloon aortic val- 
vuloplasty. The entire study cohort was analyzed according to 
whether the patient had balloon aortic valvuloplasty alone or 
subsequently progressed to surgical valve replacement. 
Valvuloplasty procedure. Balloon aortic valvuloplasty was 
performed after informed consent had been obtained in accor- 
dance with a protocol approved by the Duke University 
Medical Center Institutional Review Board. The retrograde 
technique was used in 164 patients. The anterograde t chnique 
was used in one patient. Balloon dilation was sequentially 
performed with single or double balloons of progressively 
larger effective diameters. Left ventricular and aortic pressures 
were simultaneously measured immediately before and after 
balloon aortic valvuloplasty with dual-sensor, high fidelity 
micromanometer catheters (Millar Inc.). R wave gated 
masked-mode digital subtraction left ventriculography and 
supravalvular aortography were obtained before and after 
valvuloplasty in 150 patients. Oxygen consumption was mea- 
sured with a metabolic art, and Fick cardiac output was 
obtained. The effective aortic valve area was calculated using 
the Gorlin formula (9). Coronary artery disease was defined as 
>50% lumen narrowing of a major epicardial coronary. 
Echocardiography. Transthoracic echocardiographic data 
were obtained with a Hewlett-Packard 77020A phased-array 
sector scanner immediately before valvuloplasty. Left ventric- 
ular end-diastolic dimension was measured from the paraster- 
nal view using M-mode or two-dimensional imaging. Mitral 
regurgitation was evaluated by color flow Doppler technique 
and graded in a semiquantitative fashion from 0 (absent) to 4 + 
(severe). 
Clinical follow-up. Patient status was evaluated by physi- 
cian interview and examination before balloon aortic valvulo- 
plasty and 3, 6 and 12 months afterward. The status of patients 
surviving > 1 year after valvuloplasty was assessed thereafter by 
annual telephone interviews. Final telephone follow-up was 
performed in May 1992. When patients developed symptoms 
of aortic valve restenosis, they were treated with either contin- 
ued medical therapy, a second balloon aortic valvuloplasty or 
aortic valve replacement. End points were achieved when the 
patient died, underwent aortic valve replacement, underwent 
repeat balloon aortic valvuloplasty orsurvived to the last day of 
possible contact (May 20, 1992). If death occurred, telephone 
interviews with both the primary care physician and family 
were obtained to classify the cause of death as either cardiac or 
noncardiac. Duration of follow-up was defined as the time 
from the date of balloon aortic valvuloplasty othe last day of 
contact. 
Statistics. Continuous variables are expressed as the me- 
dian and 25th and 75th percentiles. Categoric variables are 
expressed as percentages. 
The Kaplan-Meier method (10) was used to characterize 
post-aortic valvuloplasty actuarial and event-free survival. The 
actuarial survival rate was calculated from the time of the 
initial balloon aortic valvuloplasty until death. The event-free 
survival was calculated from the time of initial aortic valvulo- 
plasty until death, repeat balloon aortic valvuloplasty or aortic 
valve replacement. Survival for all patients was censored at the 
time of last contact. 
The Cox proportional hazards regression method (11) was 
used to examine the univariable association of clinical, cathe- 
terization and echocardiographic variables with event-free 
survival. Multivariable associations within these same groups 
(clinical, catheterization and echocardiography) were also 
evaluated. Those variables found significant within each of 
these three groups were combined, and, with stepwise regres- 
sion techniques, a model of the multivariable association of all 
potential variables was derived. A subgroup analysis compar- 
ing the actuarial survival of patients treated with balloon aortic 
valvuloplasty alone or subsequent aortic valve replacement was 
performed. The actuarial survival of these subgroups was 
corrected for differences intheir baseline characteristics. Com- 
parison of baseline subgroup characteristics was made using 
the Wilcoxon two-sample t st for the continuous variables and 
the chi-square test with two degrees of freedom for the 
dichotomous variables. A Cox proportional hazards model 
(11) was then developed that included the important baseline 
characteristics of age, ejection fraction, gender, angina, con- 
gestive heart failure, syncope and mitral regurgitation. 
Results 
Baseline characteristics. Balloon aortic valvuloplasty was 
performed in 165 patients. Eighty-two percent of the proce- 
dures were performed in the years 1987 to 1989 (Fig. 1), and all 
patients were eligible for at least 1 year of clinical follow-up. 
This cohort was elderly and highly symptomatic; 39% had 
angina, 79% had congestive heart failure and 33% had had 
syncope (Table 1). Fifty-two percent of patients had significant 
coronary artery disease in at least one vessel. 
Hemodynamic results. Balloon aortic valvuloplasty imme- 
diately reduced the peak-to-peak transvalvular pressure gradi- 
ent from 68 (50, 88) to 38 (28, 50) mm Hg. Median aortic valve 
area increased from 0.5 (0.4, 0.6) to 0.7 (0.6, 0.9) cm 2. Left 
ventricular systolic pressure decreased from 205 (180, 233) to 
178 (155, 200) mm Hg and left ventricular end-diastolic 
pressure from 20 (15, 28) to 15 (10, 23) mm Hg. Left ventricular 
ejection fraction increased a median of 3% (0%, 6%) from a 
prevalvuloplasty median of 53% (32%, 61%). 
Long-term outcome. Follow-up data were available for 
164 patients (99%). During the period of follow-up, 152 
(93%) patients died or underwent aortic valve replacement, 
and 99 patients (60%) died of cardiac-related causes. The 
patient with the longest event-free survival died of cardiac 
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Figure 1. Number of balloon aortic valvuloplasty pro- 
cedures by year. 
causes 4.3 years after undergoing a balloon aortic valvulo- 
plasty. Surgical aortic valve replacement was performed 
during the postvalvuloplasty period in 42 patients (25%), 
and 31 patients (19%) underwent a second balloon aortic 
valvuloplasty. 
The probability of event-free survival 1, 2 and 3 years after 
balloon aortic vaivuloplasty was 40%, 19% and 6%, respec- 
tively (Fig. 2). Event-free outcome 1 year after balloon aortic 
valvuloplasty was similar for patients with angina, syncope and 
New York Heart Association congestive heart failure classes I 
to III. However, comparison of the event-free survival curves 
in Figure 3 suggests that patients with class IV congestive heart 
failure had major events earliest. The median time from 
balloon valvuloplasty odeath or aortic valve replacement was 
10.5 (3.7, 21.3) months. 
If actuarial survival is defined as existence free of death, 
then the median actuarial survival after balloon aortic valvu- 
loplasty was 1.8 (0.7, 4.5) years; survival 1, 2 and 3 years after 
the procedure was 64%, 48% and 37%, respectively (Fig. 2). 
Examining actuarial survival by postvalvuloplasty treatment 
reveals a great disparity in survival patterns. Survival 1 year 
after balloon aortic valvuloplasty was 52% in patients treated 
Table 1. Baseline Characteristics 
All p 
Characteristic Patients BAV Only BAV + AVR Value* 
Age (yr) 78 (72, 83) 80 (74, 83) 73 (68, 75) 0.001 
Men/women 71/94 49/74 22/20 NS 
Symptom 
Angina (NYHA class III or IV) 64 (39%) 43 (35%) 21 (50%) NS 
CHF (NYHA class III or IV) 131 (79%) 101 (82%) 30 (72%) NS 
Syncope 54 (33%) 39 (32%) 15 (36%) NS 
No. of coronary arteries 
narrowed >50% 0.005-~ 
0 80 (48%) 50 (42%) 30 (71%) 
1 39 (24%) 32 (26%) 7 (17%) 
2 22 (13%) 20 (16%) 2 (5%) 
3 23 (14%) 20 (16%) 3 (7%) 
Ejection fraction (%) 53 (32, 61) 52 (31, 61) 56 (37, 61) NS 
Echocardiography 
LVIDD (cm) 4.7 (4.1, 5.4) 4.6 (4.0, 5.6) 4.7 (4.3, 5.5) NS 
MR >-2+ 47 (28%) 41 (34%) 6 (14%) 0.02 
*Balloon aortic valvuloplasty (BAV) only versus patients who subsequently underwent aortic valve replacement 
(BAV + AVR). tZero- versus one-vessel coronary disease. Data presented are median (25th, 75th percentile), number 
of patients or number (%) of patients. CHF = congestive h art failure; LVIDD = left ventricular diastolic internal 
diameter; MR = mitral regurgitation; NYHA = New York Heart Association functional c ass. 
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with balloon valvuloplasty alone versus 95% in patients treated 
by balloon valvuloplasty and subsequent aortic valve replace- 
ment (Fig. 4). Even after correcting for important differences 
in the baseline characteristics of age, ejection fraction, gender, 
angina, congestive heart failure, syncope and mitral regurgita- 
tion, the difference in actuarial survival between the balloon 
valvuloplasty only and balloon valvuloplasty plus aortic valve 
replacement groups remained highly significant (chi-square 
36.4, p < 0.00001). 
The forty-two patients who underwent elective aortic valve 
replacement did so 0.6 (0.2, 1.3) years after undergoing balloon 
aortic valvuloplasty, The duration of postoperative follow-up 
in this group, defined as the time elapsed from the date of 
aortic valve replacement to May 20, 1992 was 3.3 years. One 
hundred percent follow-up of this subgroup was achieved, and 
the probability of survival 1 year after aortic valve replacement 
was 88%. At the time of last contact, there were 17 deaths in 
this subgroup (40%), including 1 operative death, 5 nonopera- 
tive noncardiac deaths and 11 nonoperative cardiac deaths. Of 
the remaining 25 survivors, only 2 (8%) had New York Heart 
Association class III or IV heart failure, and 1 (4%) had class 
III or IV angina. 
Predictors of patient outcome. The baseline clinical, hemo- 
dynamic and echocardiographic variables and their univariable 
association with any major cardiac event (death, repeat balloon 
aortic valvuloplasty or aortic valve replacement) are shown in 
Table 2. Younger age and functional class IV congestive heart 
failure were the only clinical variables associated with a major 
cardiac event. Other predictors of major adverse vents were 
the presence of coronary artery disease, low ejection fraction, 
Figure 2. Actuarial and event-free survival after balloon aortic valvu- 
loplasty illustrating the probability ofactuarial nd event-free survival 
from the date of initial balloon aortic valvuloplasty. Events are defined 
as death, aortic valve replacement (AVR) or a second balloon aortic 
valvuloplasty (repeat BAV). 
high left ventricular end-diastolic pressure and increased left 
ventricular internal diastolic diameter. No procedural variables 
predicted event-free survival, including the reduction in aortic 
valvular gradient or the increase in aortic valve area. In 
multivariable analysis, only younger age and a lower left 
ventricular ejection fraction contributed independent adverse 
prognostic information. Jointly, they had a chi-square of 14.89 
(p = 0.0006). 
Discuss ion  
Patient outcome. The long-term outcome of adults under- 
going balloon aortic valvuloplasty has been incompletely de- 
scribed. Previous tudies (1-4,6-8,12-15) evaluating the out- 
come after balloon aortic valvuloplasty have been limited by 
reporting only short- and midterm outcome and have not 
examined clinical, hemodynamic and echocardiographic data 
in the same cohort of patients (15). Therefore, prognostic 
information available from a complete patient evaluation has 
not previously been available. The present study describes the 
outcome (up to 6 years) of 165 consecutive patients undergo- 
ing balloon aortic valvuloplasty for severe, symptomatic aortic 
stenosis. The long-term outcome after balloon aortic valvulo- 
plasty in this cohort is poor, as illustrated by a 94% probability 
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Figure 3. Event-free survival after balloon aortic valvuloplasty was 
similar for patients with syncope, angina and functional class IV 
congestive heart failure (FC 4 CHF). Patients with congestive h art 
failure tended to have events earliest. 
of death, aortic valve replacement or repeat balloon aortic 
valvuloplasty within 3 years of the initial procedure. In our 
model, event-flee survival is best predicted by patient age and 
left ventricular ejection fraction. 
The long-term nature of the present study allows compar- 
ison of the outcome in these patients with what is known of the 
natural history of untreated aortic stenosis. In their early 
review of studies based on postmortem examinations, Ross and 
Braunwald (16) emphasized the poor prognosis of patients 
with symptomatic aortic stenosis. Symptoms had existed for <4 
years in 80% of the patients who died of aortic stenosis; the 
average survival of patients with angina was 5 years, with 
syncope 3years and with congestive heart failure 2 years (16). 
However, the epidemiology of the etiology of aortic stenosis 
has changed from these earlier studies from rheumatic to 
degenerative calcific aortic stenosis (17), and the correlation 
between survival and type of symptom now appears poor (18). 
The presence of any symptom, and not the type of symptom, 
portends apoor prognosis (18,19), and the study by O'Keefe et 
al. (20) illustrates the particularly poor prognosis of candidates 
for balloon aortic valvuloplasty. They found that the 1-, 2- and 
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Figure 4. Actuarial survival from 
the date of balloon aortic valvulo- 
plasty in patients who subsequently 
underwent aortic valve replace- 
ment (BAV + AVR) and those 
treated by balloon aortic valvulo- 
plasty alone (BAY only). 
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Table 2. Baseline Univariable Predictors of Event-Free Survival 
Sign of 
Findings Chi-Square p Value Coelficient 
Clinical 
Age 11.87 0.0006 - 
CHF NYHA class IV 5.08 0.02 + 
Angina 2.01 0.16 + 
Female gender 1.50 0.22 - 
Syncope 0.65 0.42 - 
Catheterization 
Ejection fraction 8.78 0.0031 - 
LVEDP 5.08 0.02 + 
Cardiac output 2.80 0.09 - 
Coronary disease 4.00 0.045 + 
Aortic valve area 1.00 0.32 - 
Peak gradient 0.67 0.41 - 
Aortic insufficiency 0.02 0.88 + 
Echocardiographic 
LVIDD 6.58 0.01 + 
MR ->2+ 0.099 0.75 + 
LVEDP = left ventricular end-diastolic pressure; other abbreviations a in 
Table 1. 
3-year actuarial survival rate of 50 elderly patients (mean age 
77 years) referred to the Mayo Clinic with symptomatic aortic 
stenosis, in whom aortic valve replacement or balloon valvu- 
loplasty was not performed, was 57%, 37% and 25%, respec- 
tively. In our elderly study cohort (mean age 76 years), the 
event-free survival rate 1, 2 and 3 years after balloon valvulo- 
plasty was 40%, 19% and 6%, respectively, and the corre- 
sponding actuarial survival rate was 64%, 48% and 37%, 
respectively. After exclusion of the 42 patients who underwent 
aortic valve replacement after balloon aortic valvuloplasty, the 
1-, 2- and 3-year postvalvuloplasty actuarial survival rate of the 
remaining patients was 52%, 31% and 18%, respectively. 
Although a comparison cohort such as that of O'Keefe et al. 
(20) cannot fully substitute for an age-matched control group, 
the similar survival patterns of the Mayo group and our 
valvuloplasty group suggest hat balloon aortic valvuloplasty 
does not alter the dismal ong-term prognosis of patients with 
aortic stenosis. 
Predictors of outcome. Previous studies (1-8,11-14) of 
short-, mid- and long-term outcome after balloon aortic valvu- 
loplasty illustrate its beneficial palliative effect on aortic steno- 
sis symptoms and hemodynamic variables. However, the ben- 
efit is of brief duration, and most patients develop evidence of 
restenosis within 6 months of valvuloplasty (6-8). The present 
study indicates that long-term event-free survival is best pre- 
dicted by patient age and left ventricular ejection fraction. 
Other studies (12,13,15,21) have found that the best predictors 
of clinical improvement after valvuloplasty are variables re- 
flecting left ventricular function. The present study demon- 
strates that variables of left ventricular function, including 
functional class IV congestive heart failure symptoms, reduced 
ejection fraction and increased left ventricular internal dia- 
stolic diameter, are also powerful predictors of long-term 
event-free survival. 
The data indicate that younger age is associated with a 
poorer event-free survival but better actuarial survival. This 
apparent contradiction may be explained by the way patients 
were treated after their initial balloon aortic valvuloplasty. If
one analyzes the event-free survival of the entire 165-patient 
cohort, "nonsurvivors" include the 42 patients treated with 
balloon valvuloplasty who then had valve replacement, the 12 
patients who underwent a repeat balloon valvuloplasty and all 
the patients who died during follow-up. The few remaining 
event-free survivors were a particularly elderly subgroup who 
may have been excluded from subsequent procedures because 
of coexisting medical conditions. The very advanced age of this 
small remaining subgroup thereby directed the analysis of 
event-free survival toward the conclusion that younger patients 
had poorer event-free survival. 
As the actuarial survival analysis demonstrates, the best 
possible outcome for the patients in our study was not to be 
"event free." Instead, subsequent aortic valve replacement was 
associated with the greatest probability of actuarial survival. 
Patients in group receiving follow-up aortic valve replacement 
were a younger subset of the 165 patient study cohort, and 
their superb actuarial survival influenced the conclusion that 
younger age was associated with improved actuarial survival. 
Aortic valve replacement. In an era when aortic valve 
replacement may be performed in selected patients >70 years 
old with low operative risk and excellent long-term results 
(22-24), the utility of balloon aortic valvuloplasty appears 
limited. It has been thought of as a viable alternative for the 
especially frail and elderly patient. During our early experience 
with balloon aortic valvuloplasty, all of our patients were seen 
by a cardiovascular surgeon who agreed with the assessment of 
high surgical risk and the appropriateness of balloon aortic 
valvuloplasty. Aortic valve replacement was recommended 
only after symptomatic restenosis developed. The 42 patients 
in the present study who underwent aortic valve replacement 
after balloon aortic valvuloplasty did surprisingly well, with a 
1-year median actuarial survival rate of 95% from the time of 
balloon valvuloplasty and 88% from the time of operation. 
This result compares with a median 1-year actuarial survival 
rate of only 52% in the remaining patients treated by balloon 
aortic valvuloplasty alone. Remarkably, only 1 of the 42 
surgical patients died of procedure-related causes. 
Study limitations. The present study was not randomized 
with regard to use of medical therapy, balloon aortic valvulo- 
plasty and aortic valve replacement for high risk patients with 
severe aortic stenosis. During the 5-year period of patient 
enrollment, the criteria for performing delayed aortic valve 
replacement versus a second balloon aortic valvuloplasty were 
evolving. The fact that an individual patient may have under- 
gone an initial balloon aortic valvuloplasty and a subsequent 
aortic valve replacement does not imply that the patient's 
condition improved uring the interval between the two inter- 
ventions; rather, it is a reflection of our growing understanding 
of the limited utility of balloon aortic valvuloplasty. 
The present study lacks an age-matched control cohort for 
the entire study group and for the 42 patients who progressed 
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to aortic valve replacement. The study group is generally an 
especially elderly and ill group in whom balloon aortic valvu- 
loplasty was pursued because of perceived excessive surgical 
risk. The lack of a matched control group may obscure any 
potential benefit conferred by the balloon aortic valvuloplasty. 
In addition, the 42 patients who proceeded to delayed 
aortic valve replacement had significant demographic differ- 
ences from the 123 patients who continued with medical 
treatment. The surgical group was younger, included more 
men than women and had less coronary artery disease, a 
slightly higher median ejection fraction and less mitral regur- 
gitation than the balloon valvuloplasty-only group. Because the 
subgroup roceeding to delayed aortic valve replacement was 
in general healthier than the balloon valvuloplasty-only group, 
a selection bias was introduced that most likely accounts for 
some of the survival difference between the two groups. 
However, after a statistical adjustment for these differences in
baseline characteristics, the difference in survival between the 
groups remained statistically significant. 
The conclusions of this study are limited to an adult patient 
cohort and should not be extrapolated to pediatric patients, 
where balloon aortic valvuloplasty may be performed with 
more favorable results (25). 
Conclusions. Long-term event-free and actuarial survival 
after balloon aortic valvuloplasty is dismal and resembles the 
natural history of critical aortic stenosis. Aortic valve replace- 
ment may be performed in selected patients after balloon 
valvuloplasty with good results; however, the prognosis of the 
remainder of medically treated patients is particularly grim. 
Because the beneficial effects of balloon aortic valvuloplasty 
are transient, his procedure is most appropriately used when 
short-term palliation is desired, such as in patients with a 
reduced life expectancy because of comorbid illness. Over the 
longer term, balloon aortic valvuloplasty does not appear to 
alter the natural history of untreated aortic stenosis. 
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